Selected as Finalist for RESI JPM Innovator’s Pitch Challenge 2026

Brisbane, Australia – December 27, 2025 – Ketim Technologies has been shortlisted as a finalist in the RESI JPM Innovator’s Pitch Challenge, to be held during RESI JPM Week in January 2026.

The Innovator’s Pitch Challenge, hosted by Life Science Nation, showcases emerging life science companies demonstrating high-impact innovation and strong commercial potential to global investors during JPM Week.

Ketim’s selection recognises its development of the world’s first predictive blood-based diagnostic for postpartum depression and its broader precision psychiatry platform integrating biomarker discovery with AI-driven analytics.

Dr. Clarissa Yates, Founder and CEO, and Co-Founder Dr. Maciej Trzaskowski will represent the company at the event, presenting Ketim’s translational progress, validation strategy, and pathway toward regulatory and global market entry.

“We are honoured to be shortlisted among a competitive group of innovators,” said Dr. Yates. “RESI JPM provides an important platform to engage with international investors and partners committed to advancing transformative healthcare technologies.”

Ketim’s participation also reflects the strength of Queensland’s growing MedTech ecosystem, with support from the Brisbane Economic Development Agency MedTech Accelerator cohort.

The company looks forward to engaging with global investors and collaborators as it advances toward clinical validation and commercial readiness.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au